SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its initial public offering of 5,333,334 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Impel. The shares are expected to begin trading on The Nasdaq Global Market on April 23, 2021 under the symbol “IMPL.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Impel, are expected to be $80.0 million. In addition, Impel has granted the underwriters a 30-day option to purchase up to an additional 800,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 27, 2021, subject to the satisfaction of customary closing conditions.
Menu
